{"id":6991,"date":"2020-08-13T14:15:33","date_gmt":"2020-08-13T12:15:33","guid":{"rendered":"https:\/\/patientenstimme-sma.de\/?page_id=6991"},"modified":"2026-03-16T21:04:50","modified_gmt":"2026-03-16T20:04:50","slug":"srk-015-von-scholar-rock-erhaelt-deklaration-als-medikament-fuer-seltene-paediatrische-erkrankungen","status":"publish","type":"post","link":"https:\/\/smartunity.space\/stories\/thema\/srk-015-von-scholar-rock-erhaelt-deklaration-als-medikament-fuer-seltene-paediatrische-erkrankungen\/","title":{"rendered":"SRK-015 von Scholar Rock erh\u00e4lt Deklaration als Medikament f\u00fcr seltene p\u00e4diatrische Erkrankungen"},"content":{"rendered":"\n<div class=\"wp-block-group alignwide has-subtle-background-color has-background is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"tw-text-wide\">Wie in der heutigen <a href=\"https:\/\/investors.scholarrock.com\/news-releases\/news-release-details\/scholar-rock-announces-srk-015-has-received-rare-pediatric\" data-type=\"URL\" data-id=\"https:\/\/investors.scholarrock.com\/news-releases\/news-release-details\/scholar-rock-announces-srk-015-has-received-rare-pediatric\">Pressemittleilung<\/a> von Scholar Rock bekannt gegeben, hat die FDA, Scholar Rock&#8217;s, in Entwicklung zur Behandlung der spinalen Muskelatrophie befindliches &#8220;SRK-015&#8221;, als Medikament f\u00fcr seltene p\u00e4diatrische Erkrankungen ausgezeichnet bzw. deklariert.<\/p>\n\n\n\n<p class=\"tw-text-wide\">Laut Meldung gew\u00e4hrt die FDA diese Bezeichnung bei schweren lebensbedrohlichen Krankheiten, bei denen vorrangig Kinder unter 18 Jahren betroffen sind, und deren Anzahl geringer als 200.000 ist.<\/p>\n\n\n\n<p class=\"tw-text-wide\">In Verbindung mit der vorher erteilten Bezeichung als Medikament f\u00fcr seltene Erkrankungen (Orphan Drugs) unterstreiche dies die &#8220;Annerkennung der FDA f\u00fcr die ungedeckten medizinischen Bed\u00fcrfnisse von Patienten mit SMA&#8221;<\/p>\n\n\n\n<p class=\"tw-text-wide\">Quelle: <a rel=\"noreferrer noopener\" href=\"https:\/\/investors.scholarrock.com\/news-releases\/news-release-details\/scholar-rock-announces-srk-015-has-received-rare-pediatric\" data-type=\"URL\" data-id=\"https:\/\/investors.scholarrock.com\/news-releases\/news-release-details\/scholar-rock-announces-srk-015-has-received-rare-pediatric\" target=\"_blank\"><strong>Scholar Rock, Inc<\/strong><\/a><\/p>\n\n\n\n<p class=\"tw-text-wide\">Anbei die <a href=\"https:\/\/sma.selfempowered.net\/wp-content\/uploads\/sites\/2\/2020\/08\/Scholar-Rock-Announces-that-SRK-015-has-Received-Rare-Pediatric-Disease-Designation-from-U.S.-FDA-for-the-Treatment-of-Spinal-Muscular-Atrophy.pdf\">englischsprachige offizielle Pressemitteilung im Download<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Wie in der heutigen Pressemittleilung von Scholar Rock bekannt gegeben, hat die FDA, Scholar Rock&#8217;s, in Entwicklung zur Behandlung der spinalen Muskelatrophie befindliches &#8220;SRK-015&#8221;, als Medikament f\u00fcr seltene p\u00e4diatrische Erkrankungen ausgezeichnet bzw. deklariert. Laut Meldung gew\u00e4hrt die FDA diese Bezeichnung bei schweren lebensbedrohlichen Krankheiten, bei denen vorrangig Kinder unter 18 Jahren betroffen sind, und deren [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"only-view","format":"standard","meta":{"activitypub_content_warning":"","activitypub_content_visibility":"","activitypub_max_image_attachments":0,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"","footnotes":""},"categories":[1],"tags":[58],"class_list":["post-6991","post","type-post","status-publish","format-standard","hentry","category-thema","tag-smanews"],"_links":{"self":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/6991","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/comments?post=6991"}],"version-history":[{"count":1,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/6991\/revisions"}],"predecessor-version":[{"id":39817,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/6991\/revisions\/39817"}],"wp:attachment":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/media?parent=6991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/categories?post=6991"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/tags?post=6991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}